Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
Background Patients with type 2 myocardial infarction (T2MI) and other mechanisms of nonthrombotic myocardial injury have an unmet therapeutic need. Eligibility for novel medical therapy is generally uncertain.Methods We predefined colchicine, eplerenone and ticagrelor as candidates for repurposing...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2021-02-01
|
| Edice: | Open Heart |
| On-line přístup: | https://openheart.bmj.com/content/8/1/e001633.full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|